DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

• Authors: Bartenschlager R, Berger C, Bobardt M, Chatterji U, Coelmont L, Gallay P, Hanoulle X, Lim P, Lippens G, Neyts J, Paeshuyse J, Snoeck J, Vliegen I, Vuagniaux G, Vandamme AM
• Journal: PLoS One
• Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=DEB025+(Alisporivir)+Inhibits+Hepatitis+C+Virus+Replication+by+Preventing+a+Cyclophilin+A+Induced+Cis-Trans+Isomerisation+in+Domain+II+of+NS5A

DEB025/Debio 025 (Alisporivir) is a cyclophilin (Cyp)-binding molecule with potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. It is currently being evaluated in phase II clinical trials. DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication.
Read More